CMC Post-Approval Changes: SUPAC Framework and Regulatory Strategy

CMC Post-Approval Changes: SUPAC Framework and Regulatory Strategy

Key Takeaways

The SUPAC Framework

Origins and Purpose

The SUPAC guidances were developed by FDA's Center for Drug Evaluation and Research (CDER) in the mid-1990s to address a fundamental problem: 21 CFR 314.70 provides general criteria for categorizing post-approval changes but does not specify the exact tests and data required for specific change types. Applicants and FDA reviewers needed a common framework to determine what data was sufficient to support a particular change.

Before SUPAC, applicants often over-filed (submitting PAS for changes that could have been CBE-30) or under-filed (submitting CBE-30 for changes that required PAS), leading to inefficiency for both industry and the agency.

The SUPAC guidances resolved this by defining specific change levels for specific types of changes across four categories:

1. Components and Composition (excipient changes)
2. Manufacturing Site (facility changes)
3. Scale of Manufacturing (batch size changes)
4. Manufacturing Process and Equipment (process changes)

For each category, the guidances define three levels of change based on potential impact, the corresponding reporting category, and the specific tests required.

SUPAC Guidance Documents

What SUPAC Does Not Cover

SUPAC guidances do not cover all dosage forms. Notably absent are:

• Sterile injectable products
• Inhalation products (metered dose inhalers, dry powder inhalers)
• Transdermal delivery systems
• Ophthalmic products
• Parenteral products
• Biological products

For these dosage forms, applicants must rely on the general criteria in 21 CFR 314.70 (or 601.12 for biologics), relevant product-specific FDA guidances, and scientific judgment to determine the appropriate reporting category and supporting data.

SUPAC-IR: Immediate-Release Solid Oral Dosage Forms

Components and Composition Changes

This category covers changes to excipients in the formulation.

Important note on functional vs. non-functional excipients: SUPAC does not use these terms explicitly, but FDA's subsequent guidance on biowaivers (BCS-based biowaivers, 21 CFR 320.22) distinguishes between excipients that affect drug release and those that do not. Changes to excipients that directly control drug release (e.g., disintegrants, surfactants for BCS Class II drugs) are treated more conservatively.

Manufacturing Site Changes

Key distinction for site changes: Level 2 requires that the new site uses the same type of equipment (same operating principle, same class per the Equipment Addendum) and follows the same standard operating procedures. If the new site uses different equipment types or fundamentally different procedures, the change is Level 3.

Scale (Batch Size) Changes

Note: SUPAC-IR defines only two levels for scale changes (Level 1 and Level 2). There is no Level 3 batch size change defined in SUPAC-IR. However, if the scale change also involves equipment type changes or process parameter changes beyond the validated ranges, those elements may independently qualify as Level 3 under the Manufacturing Process category.

Manufacturing Process Changes

SUPAC-MR: Modified-Release Solid Oral Dosage Forms

SUPAC-MR follows the same four-category structure as SUPAC-IR but with more stringent requirements reflecting the greater complexity and criticality of modified-release drug delivery.

Key Differences from SUPAC-IR

Components and Composition Changes (SUPAC-MR)

Critical concept — release-controlling excipients: In modified-release dosage forms, certain excipients directly control the rate and extent of drug release (e.g., HPMC in a matrix tablet, coating polymers in a coated bead). Any qualitative change to these excipients (changing the polymer type) is automatically a Level 3 change requiring PAS, regardless of the magnitude of the quantitative change.

Manufacturing Process Changes (SUPAC-MR)

SUPAC-SS: Nonsterile Semisolid Dosage Forms

SUPAC-SS covers creams, ointments, gels, lotions, and pastes. Semisolid products present unique challenges because:

• Product performance depends on microstructure (particle size, emulsion stability, rheology)
• Bioavailability is difficult to assess without clinical studies
• In vitro release testing (IVRT) and in vitro permeation testing (IVPT) are used as surrogates for bioequivalence

Components and Composition Changes (SUPAC-SS)

Unique Semisolid Testing Requirements

The Equipment Addendum

Equipment Classification System

The SUPAC Equipment Addendum (1999, updated 2014) provides a classification system for pharmaceutical manufacturing equipment. Equipment is organized into classes and sub-classes based on operating principle.

The classification matters because SUPAC defines Level 2 process changes as those involving equipment within the same class but different sub-class, while Level 3 changes involve equipment in a different class.

Equipment Classes (Examples)

Example application:

• Changing from a V-blender (Class I, Sub-class A) to a double cone blender (Class I, Sub-class B): Level 2 change (same class, different sub-class)
• Changing from a V-blender (Class I) to a high-shear mixer (Class III): Level 3 change (different class)

Data Requirements in Detail

Dissolution Testing Requirements

SUPAC guidances specify dissolution testing requirements based on change level. The specifics vary by guidance:

SUPAC-IR Dissolution Requirements:

f2 Similarity Factor:

The f2 test is the standard method for comparing dissolution profiles per SUPAC and FDA guidance. The formula compares the average dissolution values at each timepoint:

• f2 >= 50 indicates similarity
• If both pre-change and post-change products dissolve >85% in 15 minutes, f2 comparison is unnecessary (profiles are considered similar by definition)
• A minimum of 12 individual dosage units should be tested per product

Stability Testing Requirements

ICH Q1A(R2) storage conditions apply:

Comparability Protocols in the SUPAC Context

Using Comparability Protocols to Reduce Reporting

Under 21 CFR 314.70(a)(2)(ii), an applicant can submit a comparability protocol that, once approved by FDA, allows future changes meeting the protocol's criteria to be filed at a reduced reporting category. In the SUPAC context, this means a Level 3 change that would normally require a PAS could be filed as a CBE-30 if:

1. The applicant submitted a comparability protocol describing the change type
2. FDA approved the comparability protocol (via PAS-level review)
3. The actual change meets all criteria specified in the approved protocol
4. The supporting data demonstrate the post-change product meets the protocol's acceptance criteria

Practical Application

Comparability protocols are most useful for companies that anticipate making similar changes repeatedly, such as:

• Multi-product manufacturers planning to transfer multiple products to a new site
• Companies with multiple strengths of the same product that will all undergo the same process change
• Organizations planning phased manufacturing improvements across their portfolio

ICH Q12 and the Future of Post-Approval Change Management

Established Conditions (ECs)

ICH Q12 (Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management), finalized in November 2019, introduces the concept of Established Conditions (ECs). ECs are the specific elements of a regulatory filing that, if changed, require regulatory notification. Elements not designated as ECs can be managed within the company's pharmaceutical quality system without regulatory filing.

This concept refines the SUPAC approach by making explicit which elements of the manufacturing process are regulatory commitments and which are internal controls.

Post-Approval Change Management Protocols (PACMPs)

PACMPs, defined in ICH Q12, are the international equivalent of FDA's comparability protocols. They provide a globally harmonized framework for prospective change management.

Key differences from FDA comparability protocols:

Product Lifecycle Management (PLCM) Document

ICH Q12 also introduces the PLCM document, a summary of ECs and approved PACMPs for a product. This document is maintained throughout the product lifecycle and serves as a reference for both the applicant and regulatory authorities.

Common Regulatory Strategy Decisions

When to Use SUPAC vs. General 314.70 Criteria

Handling Multiple Simultaneous Changes

When an applicant makes several changes at the same time, each change should be evaluated independently against the applicable SUPAC guidance. However, the overall filing category is determined by the highest-level change. For example:

• Level 1 site change + Level 2 batch size change = CBE-30 supplement (driven by the Level 2 change)
• Level 2 process change + Level 3 formulation change = PAS (driven by the Level 3 change)

FDA also expects applicants to consider the cumulative effect of multiple changes. Even if each individual change is Level 1, the combination of multiple Level 1 changes may collectively constitute a Level 2 or Level 3 change if they interact or compound risk.

Key Regulatory References

References